1. Home
  2. SW vs GMAB Comparison

SW vs GMAB Comparison

Compare SW & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smurfit WestRock plc Ordinary Shares

SW

Smurfit WestRock plc Ordinary Shares

HOLD

Current Price

$43.32

Market Cap

20.6B

Sector

N/A

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$25.08

Market Cap

16.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SW
GMAB
Founded
1934
1999
Country
Ireland
Denmark
Employees
97000
3088
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.6B
16.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SW
GMAB
Price
$43.32
$25.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
8
Target Price
$53.58
$39.56
AVG Volume (30 Days)
4.5M
1.7M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
4.56%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.43
$17.85
Revenue Next Year
$3.13
$16.04
P/E Ratio
$38.98
$1.90
Revenue Growth
N/A
N/A
52 Week Low
$32.73
$20.23
52 Week High
$52.65
$35.43

Technical Indicators

Market Signals
Indicator
SW
GMAB
Relative Strength Index (RSI) 59.88 44.45
Support Level $40.38 $23.62
Resistance Level $44.61 $29.64
Average True Range (ATR) 1.74 0.54
MACD 0.27 -0.02
Stochastic Oscillator 95.60 41.62

Price Performance

Historical Comparison
SW
GMAB

About SW Smurfit WestRock plc Ordinary Shares

Smurfit WestRock PLC manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. operates a vertically integrated system supplying wood and recovered fiber to produce various grades of board, which are then converted into packaging products. Its main packaging categories include corrugated containers and consumer packaging, with additional products such as solidboard, kraft paper, graphic board, paper sacks, and bag-in-box packaging. The company's geographical segments include North America (including the U.S., Canada and Mexico), Europe, the Middle East and Africa and Asia-Pacific, and Latin America. The majority of the company's revenue is derived from product sales in the North American region.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: